Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Dow
Express Scripts
Mallinckrodt
Johnson and Johnson

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR NABILONE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nabilone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00272207 ↗ A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia Completed Valeant Canada Limited Phase 2 2006-04-01 The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.
NCT00272207 ↗ A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia Completed Winnipeg Regional Health Authority Phase 2 2006-04-01 The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.
NCT00381199 ↗ Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia Completed McGill University Health Center N/A 2006-04-01 Most chronic pain patients with insomnia are currently not well-managed using existing medications. If found to safely improve sleep with chronic pain patients, nabilone could be added to the treatment options available in the management of fibromyalgia and associated symptoms. The principle hypothesis of this study is that nabilone at a dose of 0.5-1mg is as efficacious as amitriptyline at a dose of 10-20mg, in improving sleep quality in patients with fibromyalgia.
NCT00381199 ↗ Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia Completed McGill University Health Centre/Research Institute of the McGill University Health Centre N/A 2006-04-01 Most chronic pain patients with insomnia are currently not well-managed using existing medications. If found to safely improve sleep with chronic pain patients, nabilone could be added to the treatment options available in the management of fibromyalgia and associated symptoms. The principle hypothesis of this study is that nabilone at a dose of 0.5-1mg is as efficacious as amitriptyline at a dose of 10-20mg, in improving sleep quality in patients with fibromyalgia.
NCT00384410 ↗ Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients Unknown status Bausch Health Americas, Inc. Phase 2 2005-12-01 Sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. Nabilone is a medication that is approved by Health Canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. However, there is no direct research evidence to either support or refute this practice. This study will investigate if nabilone is effective in improving sleep in insomnia and pain patients.
NCT00384410 ↗ Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients Unknown status Valeant Pharmaceuticals International, Inc. Phase 2 2005-12-01 Sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. Nabilone is a medication that is approved by Health Canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. However, there is no direct research evidence to either support or refute this practice. This study will investigate if nabilone is effective in improving sleep in insomnia and pain patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nabilone

Condition Name

Condition Name for Nabilone
Intervention Trials
Parkinson Disease 3
Neuropathic Pain 3
Fibromyalgia 3
Alzheimer Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nabilone
Intervention Trials
Neuralgia 5
Marijuana Abuse 4
Fibromyalgia 3
Parkinson Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nabilone

Trials by Country

Trials by Country for Nabilone
Location Trials
Canada 17
United States 7
Austria 2
Mexico 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nabilone
Location Trials
New York 4
Texas 1
Maryland 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nabilone

Clinical Trial Phase

Clinical Trial Phase for Nabilone
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 2/Phase 3 4
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nabilone
Clinical Trial Phase Trials
Completed 15
Not yet recruiting 7
Unknown status 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nabilone

Sponsor Name

Sponsor Name for Nabilone
Sponsor Trials
University of Manitoba 5
New York State Psychiatric Institute 5
Valeant Canada Limited 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nabilone
Sponsor Trials
Other 42
Industry 9
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKesson
Dow
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.